<SEC-DOCUMENT>0001193125-23-160962.txt : 20230606
<SEC-HEADER>0001193125-23-160962.hdr.sgml : 20230606
<ACCEPTANCE-DATETIME>20230605205527
ACCESSION NUMBER:		0001193125-23-160962
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230605
FILED AS OF DATE:		20230606
DATE AS OF CHANGE:		20230605

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		23994688

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d480563d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated June&nbsp;5, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 33, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d480563dex991.htm">Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual Meeting </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: June&nbsp;5, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d480563dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g480563page4b.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cell Carcinoma at ASCO 2023 Annual Meeting </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Efti plus pembrolizumab led to deep, durable responses, regardless of
<FONT STYLE="white-space:nowrap">PD-L1</FONT> expression levels, and median Duration of Response not reached despite median follow up of 39 months in <FONT STYLE="white-space:nowrap">TACTI-002</FONT> Phase II </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Promising efficacy in patients with a <FONT STYLE="white-space:nowrap">PD-L1</FONT> Combined Positive Score (CPS)
of &#8805;1 with median Overall Survival of 12.6 months, a <FONT STYLE="white-space:nowrap">12-month</FONT> Overall Survival rate of 52.0%, and a response rate of 38.5% </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patients with a <FONT STYLE="white-space:nowrap">PD-L1</FONT> CPS &#8805;20 achieved a median Overall Survival of
15.5 months, a <FONT STYLE="white-space:nowrap">12-month</FONT> Overall Survival rate of 66.7%, and a response rate of 60.0% </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">One long-lasting complete response occurred in a patient with negative
<FONT STYLE="white-space:nowrap">PD-L1</FONT> expression or CPS &lt;1 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Dual immuno-oncology approach is safe and very well tolerated </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Follow on <FONT STYLE="white-space:nowrap">TACTI-003</FONT> Phase IIb trial in 1st line HNSCC expected to report <FONT
STYLE="white-space:nowrap">top-line</FONT> results in H2 of CY2023 </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 5</B><B></B><B>&nbsp;June </B><B>2023
&#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and
autoimmune disease, today provides an overview of the positive final data from Part C of the <FONT STYLE="white-space:nowrap">TACTI-002</FONT> Phase II trial to be presented in a poster presentation at the ASCO 2023 Annual Meeting taking place in
Chicago, US. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Part C of <FONT STYLE="white-space:nowrap">TACTI-002</FONT> evaluated eftilagimod alpha (efti), a soluble
<FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> MHC Class&nbsp;II agonist, in combination with MSD&#146;s (Merck&nbsp;&amp; Co., Inc., Rahway,
NJ, USA) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) in 2nd line head and neck squamous cell carcinoma (2L
HNSCC) patients unselected for <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression (N=37), with disease progression on, or after, platinum-based therapy (&plusmn; cetuximab). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The combination of efti plus pembrolizumab led to an encouraging overall response rate (ORR) of 29.7% and Complete Response (CR) rate of 13.5% in 2L HNSCC
patients, regardless of <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression, as per iRECIST (RECIST 1.1 results were comparable). Responses were seen across all <FONT STYLE="white-space:nowrap">PD-L1</FONT> subgroups. A promising ORR of 38.5%
&amp; 60%, median Overall Survival (mOS) of 12.6 &amp; 15.5 months, and <FONT STYLE="white-space:nowrap">12-month</FONT> Overall Survival (OS) rate of 52.0% &amp; 66.7%, were seen in patients with a <FONT STYLE="white-space:nowrap">PD-L1</FONT> CPS
of &#8805;1 and a <FONT STYLE="white-space:nowrap">PD-L1</FONT> CPS &#8805;20, respectively. Despite a long median follow up of 39 months, median Duration of Response (mDoR) was not reached. (<I>Table 1</I>) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Results compare favourably to reported results from a registrational trial of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> monotherapy in the same patient population with a <FONT STYLE="white-space:nowrap">PD-L1</FONT> CPS &#8805;1, which showed a 17.3% ORR, mOS of 8.7 months, <FONT
STYLE="white-space:nowrap">12-month</FONT> OS rate of 40%, a CR rate of 2%, and mDoR of 18.4 months.<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Table 1 &#150; Efficacy Endpoints Across <FONT STYLE="white-space:nowrap">PD-L1</FONT> Subgroups in 2nd line HNSCC
<FONT STYLE="white-space:nowrap">(TACTI-002,</FONT> Part C) as per iRECIST </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Overall&nbsp;(N=37)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>CPS&nbsp;</B>&#8805;<B></B><B>1&nbsp;(N=25)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>CPS&nbsp;</B>&#8805;<B></B><B>20&nbsp;(N=15)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Overall Response Rate (ORR), %</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Median Progression-Free Survival (mPFS), months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">6-month</FONT> PFS rate, %</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Median Overall Survival (mOS), months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">12-month</FONT> OS rate, %</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Median Duration of Response (mDoR), months</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Not&nbsp;Reached</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Not&nbsp;Reached</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">Not&nbsp;Reached</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g480563page4b.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Bernard Doger of START <FONT STYLE="white-space:nowrap">Madrid-FJD,</FONT> Fundaci&oacute;n
Jim&eacute;nez D&iacute;az University Hospital and <FONT STYLE="white-space:nowrap">TACTI-002</FONT> and <FONT STYLE="white-space:nowrap">TACTI-003</FONT> investigator said, &#147;The high overall and complete response rates for patients in Part C
of the <FONT STYLE="white-space:nowrap">TACTI-002</FONT> trial, taken alongside their long-lasting persistence with the median Duration of Response not reached, provides a strong foundation for the ongoing
<FONT STYLE="white-space:nowrap">TACTI-003</FONT> trial in 1st line HNSCC. The combination of the MHC Class&nbsp;II agonist, efti, with pembrolizumab is now showing an encouraging overall survival benefit in two different cancer indications.&#148;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As seen in multiple clinical trials, efti is generating very durable responses when combined with <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-(L)1</FONT></FONT> therapies. Notably, one of the five complete responses that lasted 28 months (as of the data <FONT STYLE="white-space:nowrap">cut-off)</FONT> occurred in a patient with negative <FONT
STYLE="white-space:nowrap">PD-L1</FONT> expression or CPS &lt;1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The safety profile of efti in combination with pembrolizumab continues to be safe and
very well tolerated. No new safety signals were observed from Part C of the <FONT STYLE="white-space:nowrap">TACTI-002</FONT> Phase II trial. The dual immuno-oncology approach had adverse reactions that led to treatment discontinuation in only two
patients (5.1%)<SUP STYLE="font-size:75%; vertical-align:top">2</SUP>, which compares favorably to the treatment discontinuation rate from adverse reactions with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> monotherapy in the same patient population (6.1%).<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;It&#146;s noteworthy to see efti combined with pembrolizumab generating a response in 29.7% of patients with 2nd line HNSCC, including five patients
with complete responses, regardless of <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression. In patients expressing <FONT STYLE="white-space:nowrap">PD-L1</FONT> CPS <U>&gt;</U>1 or <FONT STYLE="white-space:nowrap">PD-L1</FONT> CPS
<U>&gt;</U>20, overall survival, progression-free survival, and response rates from the dual immuno-oncology approach compare rather favourably to reported results from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> monotherapy approved for the treatment of platinum refractory metastatic HNSCC,&#148; stated Fr&eacute;d&eacute;ric Triebel, M.D., Ph.D., Immutep&#146;s CSO.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;These final results in 2nd line HNSCC are very encouraging in a difficult to treat patient population. It was the strength of interim results from <FONT
STYLE="white-space:nowrap">TACTI-002,</FONT> along with efti&#146;s potential to address an unmet medical need, that secured FDA Fast Track designation for 1st line treatment of HNSCC. In 1st line HNSCC, we are now focused on completing enrolment
for <FONT STYLE="white-space:nowrap">TACTI-003</FONT> by <FONT STYLE="white-space:nowrap">mid-year</FONT> and expect to report <FONT STYLE="white-space:nowrap">top-line</FONT> results later in H2 of CY2023,&#148;<I> </I>said Marc Voigt,
Immutep&#146;s CEO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the abstract and information that was announced to the ASX on 26<SUP STYLE="font-size:75%; vertical-align:top">3</SUP>
and 31&nbsp;May 2023<SUP STYLE="font-size:75%; vertical-align:top">4</SUP>, the <I>Final results</I><I></I><I>&nbsp;from <FONT STYLE="white-space:nowrap">TACTI-002</FONT> Part C: A Phase II study of eftilagimod alpha (soluble <FONT
STYLE="white-space:nowrap">LAG-3</FONT> protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for <FONT STYLE="white-space:nowrap">PD-L1</FONT></I> poster will be available on
the&nbsp;<U>Posters&nbsp;&amp; Publication section</U> of Immutep&#146;s website following its presentation between <FONT STYLE="white-space:nowrap">2:15PM-5:15PM</FONT> EDT at ASCO today. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is a registered trademark of Merck Sharp&nbsp;&amp; Dohme LLC, a subsidiary of
Merck&nbsp;&amp; Co., Inc., Rahway, NJ, USA. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g480563page4b.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Eftilagimod Alpha (Efti) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is Immutep&#146;s proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist that stimulates both innate and
adaptive immunity for the treatment of cancer. As a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator, efti binds to MHC (major histocompatibility complex)
Class&nbsp;II molecules on APC leading to activation and proliferation of CD8+ cytotoxic T cells, CD4+ helper T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like <FONT
STYLE="white-space:nowrap">IFN-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> and CXCL10 that further boost the immune system&#146;s ability to fight cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is under evaluation for a variety of solid tumours including <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), head and neck
squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations, including with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy
and/or chemotherapy. Efti has received Fast Track Designation in 1st line HNSCC and in 1st line NSCLC from the United States Food and Drug Administration (FDA). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical stage biotechnology
company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT
STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its
expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong,
Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; <U>cstrong@citadelmagnus.com</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and
Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ezra E W Cohen et al., Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-and-neck</FONT></FONT> squamous cell carcinoma <FONT STYLE="white-space:nowrap">(KEYNOTE-040):</FONT> a randomised, open-label, phase 3 study; The Lancet 2019. <FONT
STYLE="white-space:nowrap">http://dx.doi.org/10.1016/S0140-6736(18)31999-8</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Relationship to efti and/or pembrolizumab could not be ruled out. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Publication of Abstracts for ASCO 2023 Annual Meeting</U> 26&nbsp;May 2023 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Immutep Capital Raising Presentation 31&nbsp;May 2023</U> &#150; slides 25 &amp; 26 </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the Board of Immutep Limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;33, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g480563page4b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g480563page4b.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /W\H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@!I;;VSC],>U-+Y)";Y4K*[;2M^OR/,/'/Q>\'^ "MMJUS-=:HZ!
MX](TU([B^V-NV23!Y(XK6-MIP9I$W8.P.1BN+$8ZAAM'+F:Z(\C,,[P.7-PJ
M5.><5K&+5_Q_KR/,=,_:E\'75Y'!?:/KNF6KN$-XZ6EU' "<>9/#;3F4(._D
MI,WHIP<<L,WH-QC*$H<VVS_(\BGQC@7*'M*%2E3E-04[QEJ]GRK6Q]&Z5J^G
M:UI]MJFE7<%]I]W&);:ZMI5EAE0]U92<$'*E3@J000",5Z=*I"K'FIRYDM#Z
MNG4A5@ITFI0ELU_6GH:0_E^E7L:+\@H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H YWQ5K \.^'=;UQD#C2=*O[]8R2/->UMI9HXLC
MD;W15X_O5E5J>SA)WLHQ;MZ'+C*OU;"UZZ5Y4X.WEV/SNTSP[9?$V[TI+3Q'
M<2_$#7M4O[G7H-6AD33DM(S/,)[&>*V<2M%:Q1M]G:4C:#&H'E@5\RJ-/&33
M4[3FW:_2WH?EM/!4LZJ1C&O_ +75E)RO>UD]+6/8]:^%:?"?3-$\67EY!XMT
MKPC<3WM[I$FFV]C)>7FIO#8VK_:I/M6+2*XEA<B02E&7*J=P"=T\'+!05>4%
M5A15G&VORO>Q]!6R:GD4,-F,X1Q,,)93@U[MV]'9W5UW8[X"?$"?5O'WB;2(
M[2'2]'\0B[UW3]'MC_HFEWEN\"S); (BJ)K=R\FU$#/ I"C.*>68KVE>2Y>6
M,M5%=/Z7Z%<-9I/$9GC:44XT*C=90;NHMI1M&VT4H['V8HP/Q_+  _I7MK=^
M3/N8JUW_ #.Z7X?H.IC"@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@!"<?A_D4 ?%&M_M'>-]/^/47PVM_"=G+X>_M^PT,JUOJ
M(UVXM[MX(I-;MYUF$(@C,QF1?LKH8806D!)EB /M9,[1G@]_:@!U !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 (3M&?3\/I0NBV#\#P"^^/6@6'C=_!LGA_4WOX]<@T'[>DEF(/-N+J
M*V67YG\SR1),I*]>.F:\^6/4*\J'LK\K2OS?I;]3YRKQ'0HX[ZC[&\U-0YN?
MN[7MR].USNOB#\2]&^'&GV5]K%IJ-W]OGEMK6'3H[=W\R&/S7:9[B>%8H]N.
M<L>1\O7'1B,1'#1C*2TEMK;I?L>AF6:X;*Z"K8AOEE)127=QE+Y:19X/<?M8
MZ>KG[+X,O)8U;&ZXUN&V<#)P=D>F3CH/[_\ C7G2S>,;VH\T5L^?\/@/EI<=
M8=:T\!.<$[<WM&OP]D_S.OT']IOP+J-I<RZO;ZCH%S:P^<MM*G]H)>88((K.
M>T3YYBV/EECA!&2"<'&U'-*%2,G/]TXJZC>_RO9?D>AA>,,JK4W*JY8><4WR
M/WMNE[1_(Y6[_:OTF.X*6/A'49[56(\^YU:VLYBHZ$6T5G<KG'\/G#D?C6$L
MYA!:4&TG;X[?^VLXJO'.#IOW,).<4[7YVM.]O9O\SV+X=?%_PS\1A-;Z:+BP
MU:TA$]QI-_L$X@#*AN+:6(F.YA5V56*D,A9=Z*&4GOPF,HXN/N/EDE?EO?\
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M[6RW#7=Q>7D @4&ZBQL64D;CMXH ^;Y?V[=+27%M\-[^6'/WYO$]M;R[0?\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 U^GXC^=-;K^N@UU]&?FUXA_P"2^3_]E#L?_3I:U\M7_P"1
ME5_QK\S\FQ/_ "4;_P"PB/\ Z4>X?M4_\@#PG_V%KW_TC6N_.?X5'^NA]'QO
M_N-#_K['_P!-5#T#]G3CX7:/[7FL_P#ISN*Z<M_W2E_B_P STN%M,GI^K_4^
M:OVF?^2EK_V+VE?I/J%>9F/^^4_(^2XO7_"OAG_T[_\ ;D?=GAC_ )%OP_\
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M3W\>H:R$=60BVU74KJ[L6VL,@/8O;OC_ &_S-O(-O(^@: "@ H * "@ H *
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MEHSC('!Z5[%.+4(K9Q6WX'UE"E.G0I0:7-3@HVOV26]M-CY6A^!OC"+XI?\
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M0+B/(+@=>37BT<!5HXM5V_=C)R2M:]^A\9AN',90S=8V<H^SYW)):_C?]#Z
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#QH?'[X5?\ 0T)Q
M_P!0K7/_ )65PK,<)_S\M8\'_63*4E^__ /^%_?"G_H:%_\ !5KG_P K*?\
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M /@'_"_OA3_T-"_^"K7/_E91_:.#_P"?OX!_K)E/_/\ _ /^%_?"G_H:%_\
M!5KG_P K*/[1P?\ S]_ /]9,I_Y__@'_  O[X4_]#0O_ (*M<_\ E91_:.#_
M .?OX!_K)E/_ #__  #_ (7]\*?^AH7_ ,%6N?\ RLH_M'!_\_?P#_63*?\
MG_\ @'_"_OA3_P!#0O\ X*M<_P#E91_:.#_Y^_@'^LF4_P#/_P# /^%_?"G_
M *&A?_!5KG_RLH_M'!_\_?P#_63*?^?_ . ?\+^^%/\ T-"_^"K7/_E91_:.
M#_Y^_@'^LF4_\_\ \ _X7]\*?^AH7_P5:Y_\K*/[1P?_ #]_ /\ 63*?^?\
M^ ?\+^^%/_0T+_X*M<_^5E']HX/_ )^_@'^LF4_\_P#\ _X7]\*?^AH7_P %
M6N?_ "LH_M'!_P#/W\ _UDRG_G_^ ?\ "_OA3_T-"_\ @JUS_P"5E']HX/\
MY^_@'^LF4_\ /_\  /\ A?WPI_Z&A?\ P5:Y_P#*RC^T<'_S]_ /]9,I_P"?
M_P" ?\+^^%/_ $-"_P#@JUS_ .5E']HX/_G[^ ?ZR93_ ,__ , _X7]\*?\
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MX!_K)E/_ #__  #_ (7]\*?^AH7_ ,%6N?\ RLH_M'!_\_?P#_63*?\ G_\
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M'^LF4_\ /_\  /\ A?WPI_Z&A?\ P5:Y_P#*RC^T<'_S]_ /]9,I_P"?_P"
M?\+^^%/_ $-"_P#@JUS_ .5E']HX/_G[^ ?ZR93_ ,__ , _X7]\*?\ H:%_
M\%6N?_*RC^T<'_S]_ /]9,I_Y_\ X!_PO[X4_P#0T+_X*M<_^5E']HX/_G[^
M ?ZR93_S_P#P#_A?WPI_Z&A?_!5KG_RLH_M'!_\ /W\ _P!9,I_Y_P#X!_PO
M[X4_]#0O_@JUS_Y64?VC@_\ G[^ ?ZR93_S_ /P#_A?WPI_Z&A?_  5:Y_\
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M_P T/Q_R#_4C%?\ 051^Z?\ D'_#*_BO_H8_#_\ WQJ/_P C4?V'7_FA^/\
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M3_R#_AE?Q7_T,?A__OC4?_D:C^PZ_P#-#\?\@_U(Q7_051^Z?^0?\,K^*_\
MH8_#_P#WQJ/_ ,C4?V'7_FA^/^0?ZD8K_H*H_=/_ "#_ (97\5_]#'X?_P"^
M-1_^1J/[#K_S0_'_ "#_ %(Q7_051^Z?^0?\,K^*_P#H8_#_ /WQJ/\ \C4?
MV'7_ )H?C_D'^I&*_P"@JC]T_P#(/^&5_%?_ $,?A_\ [XU'_P"1J/[#K_S0
M_'_(/]2,5_T%4?NG_D'_  ROXK_Z&/P__P!\:C_\C4?V'7_FA^/^0?ZD8K_H
M*H_=/_(/^&5_%?\ T,?A_P#[XU'_ .1J/[#K_P T/Q_R#_4C%?\ 051^Z?\
MD'_#*_BO_H8_#_\ WQJ/_P C4?V'7_FA^/\ D'^I&*_Z"J/W3_R#_AE?Q7_T
M,?A__OC4?_D:C^PZ_P#-#\?\@_U(Q7_051^Z?^0?\,K^*_\ H8_#_P#WQJ/_
M ,C4?V'7_FA^/^0?ZD8K_H*H_=/_ "#_ (97\5_]#'X?_P"^-1_^1J/[#K_S
M0_'_ "#_ %(Q7_051^Z?^0?\,K^*_P#H8_#_ /WQJ/\ \C4?V'7_ )H?C_D'
M^I&*_P"@JC]T_P#(/^&5_%?_ $,?A_\ [XU'_P"1J/[#K_S0_'_(/]2,5_T%
M4?NG_D'_  ROXK_Z&/P__P!\:C_\C4?V'7_FA^/^0?ZD8K_H*H_=/_(/^&5_
M%?\ T,?A_P#[XU'_ .1J/[#K_P T/Q_R#_4C%?\ 051^Z?\ D'_#*_BO_H8_
M#_\ WQJ/_P C4?V'7_FA^/\ D'^I&*_Z"J/W3_R#_AE?Q7_T,?A__OC4?_D:
MC^PZ_P#-#\?\@_U(Q7_051^Z?^0?\,K^*_\ H8_#_P#WQJ/_ ,C4?V'7_FA^
M/^0?ZD8K_H*H_=/_ "#_ (97\5_]#'X?_P"^-1_^1J/[#K_S0_'_ "#_ %(Q
M7_051^Z?^0?\,K^*_P#H8_#_ /WQJ/\ \C4?V'7_ )H?C_D'^I&*_P"@JC]T
M_P#(/^&5_%?_ $,?A_\ [XU'_P"1J/[#K_S0_'_(/]2,5_T%4?NG_D'_  RO
MXK_Z&/P__P!\:C_\C4?V'7_FA^/^0?ZD8K_H*H_=/_(/^&5_%?\ T,?A_P#[
MXU'_ .1J/[#K_P T/Q_R#_4C%?\ 051^Z?\ D'_#*_BO_H8_#_\ WQJ/_P C
M4?V'7_FA^/\ D'^I&*_Z"J/W3_R#_AE?Q7_T,?A__OC4?_D:C^PZ_P#-#\?\
M@_U(Q7_051^Z?^0?\,K^*_\ H8_#_P#WQJ/_ ,C4?V'7_FA^/^0?ZD8K_H*H
M_=/_ "#_ (97\5_]#'X?_P"^-1_^1J/[#K_S0_'_ "#_ %(Q7_051^Z?^0?\
M,K^*_P#H8_#_ /WQJ/\ \C4?V'7_ )H?C_D'^I&*_P"@JC]T_P#(/^&5_%?_
M $,?A_\ [XU'_P"1J/[#K_S0_'_(/]2,5_T%4?NG_D'_  ROXK_Z&/P__P!\
M:C_\C4?V'7_FA^/^0?ZD8K_H*H_=/_(/^&5_%?\ T,?A_P#[XU'_ .1J/[#K
M_P T/Q_R#_4C%?\ 051^Z?\ D'_#*_BO_H8_#_\ WQJ/_P C4?V'7_FA^/\
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M3_R#_AE?Q7_T,?A__OC4?_D:C^PZ_P#-#\?\@_U(Q7_051^Z?^0?\,K^*_\
MH8_#_P#WQJ/_ ,C4?V'7_FA^/^0?ZD8K_H*H_=/_ "#_ (97\5_]#'X?_P"^
M-1_^1J/[#K_S0_'_ "#_ %(Q7_051^Z?^0?\,K^*_P#H8_#_ /WQJ/\ \C4?
MV'7_ )H?C_D'^I&*_P"@JC]T_P#(/^&5_%?_ $,?A_\ [XU'_P"1J/[#K_S0
M_'_(/]2,5_T%4?NG_D'_  ROXK_Z&/P__P!\:C_\C4?V'7_FA^/^0?ZD8K_H
M*H_=/_(/^&5_%?\ T,?A_P#[XU'_ .1J/[#K_P T/Q_R#_4C%?\ 051^Z?\
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M_P T/Q_R#_4C%?\ 051^Z?\ D'_#*_BO_H8_#_\ WQJ/_P C4?V'7_FA^/\
MD'^I&*_Z"J/W3_R#_AE?Q7_T,?A__OC4?_D:C^PZ_P#-#\?\@_U(Q7_051^Z
M?^0?\,K^*_\ H8_#_P#WQJ/_ ,C4?V'7_FA^/^0?ZD8K_H*H_=/_ "#_ (97
M\5_]#'X?_P"^-1_^1J/[#K_S0_'_ "#_ %(Q7_051^Z?^0?\,L^*Q_S,>@<>
EB:AQCZVXI?V-..DY1OTMV^XA\%UZ;M+$Q;_N7M_Y,KWT]-C_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
